Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: saito k. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Shitara K, et al. Among authors: saito k. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047804 Clinical Trial.
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Tsurutani J, et al. Among authors: saito k. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213540 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: saito k. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Prognostic Value of Objective Social Isolation and Loneliness in Older Patients With Heart Failure: Subanalysis of FRAGILE-HF and Kitasato Cohort.
Saito H, Maeda D, Kagiyama N, Sunayama T, Dotare T, Fujimoto Y, Jujo K, Saito K, Uchida S, Hamazaki N, Kamiya K, Ogasahara Y, Maekawa E, Konishi M, Kitai T, Iwata K, Wada H, Kasai T, Nagamatsu H, Ako J, Momomura SI, Matsue Y. Saito H, et al. Among authors: saito k. J Am Heart Assoc. 2024 May 10:e032716. doi: 10.1161/JAHA.123.032716. Online ahead of print. J Am Heart Assoc. 2024. PMID: 38726923 Free article.
Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn's disease.
Oike T, Akizue N, Ohta Y, Koseki H, Saito M, Yokoyama Y, Imai Y, Taida T, Okimoto K, Saito K, Ogasawara S, Matsumura T, Nakagawa T, Arai M, Katsuno T, Fukuda Y, Kitsukawa Y, Kato J, Kato N. Oike T, et al. Among authors: saito k. Arab J Gastroenterol. 2024 May 6:S1687-1979(24)00036-4. doi: 10.1016/j.ajg.2024.03.006. Online ahead of print. Arab J Gastroenterol. 2024. PMID: 38714472
8,904 results